Jeff, Today's news IS interesting. Here's what I understand about the tie between ADOT and BIOMODA. It's beginning to make a LOT of sense to me.
BIOMODA EARLY CANCER DETECTION & TREATMENT:
BIOMODA Inc., a privately held bio tech company, holds a world-wide exclusive license in perpetuity from the University of California to a patented a molecular marker/binder technology for the very early detection of lung cancer AND an integrated treatment for lung cancer.
As it turns out, ADOT's patented technology used in flat panel displays also has medical applications. Specifically, BIOMODA incorporates this technology in the equipment it uses for early cancer detection and treatment of lung cancer. This technology was original used in research done by the government at Los Alamos & Sandia Laboratories.
BIOMODA has given ADOT the first right of refusal to design, manufacture and distribute the scanning test devices used for the lung cancer tests. The BIOMODA tests detect lung cancer 6 years earlier than all other tests currently used.
Consequently, ADOT recently acquired a substantial minority interest in BIOMODA.
BIOMODA estimates there are 77 million Americans over age 45 who are at risk of lung cancer. In 1991, an estimated 25 percent smoked. That represents at least 19 million people who might benefit from an annual screening for lung cancer (similar to the screening for cervical cancer in women after puberty).
The early detection cancer test can be expected to improve 5-year survival rates from at least 13% to 46%. With the advent of Biomoda's new lung cancer treatment, this diagnostic/treatment program can be expected to increase these survival rates even further.
At $100 per test, the potential annual market just for all smokers over age 45 is $1.9 Billion! For all smokers over the age of 40, it's $3 Billion !!
BIOMODA estimates the present market for lung cancer therapies is about $450 Million and BIOMODA expects to retain a significant share of that market.
So ADOT can benefit from BIOMODA's program in 2 ways:
1) ADOT has the first right of refusal to design, manufacture and distribute the scanning test devices used for the lung cancer tests.
2) ADOT also owns 20% or more of BIOMODA, Inc. BIOMODA profits will directly benefit ADOT and subsequently ADOT shareholders.
I am looking into this more, but as of right now, I think this is an extremely interesting program.
Best wishes,
Brad |
